Activity Profile of the Novel Aziridinylbenzoquinones MeDZQ and RH1 in Human Tumour Xenografts

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3979-3983

  Cummings, Jeffrey ^a,b   Ritchie, Alison ^a   Butler, John ^b   Ward, Timothy H ^b   Langdon, Simon ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Aziridinylbenzoquinones; DT diaphorase; Lung and colon xenografts; MeDZQ; RH1

Indexed keywords

AZIRIDINYLBENZOQUINONE DERIVATIVE; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UNITED KINGDOM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0344442219     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Malkinson AM, Siegel D, Forrest GL, Gadzar, AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison jr SD and Ross D: Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52: 4752-4757, 1992.
2. Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BF and Peters GJ: DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 72: 917-921, 1995.
3. Workman P: Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer drugs and quinone metabolising enzymes, particularly DT-diaphorase. Oncol Res 6: 461-475, 1994.
4. Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ and Rockwell S: Mitomycin C: A prototype bioreductive agent. Oncol Res 6: 501-508, 1994.
5. Spain RC: The case for mitomycin C in non-small cell lung cancer. Oncol 50 (suppl 1): 35-52, 1993.
6. Cummings J, Spanswick VJ, Tomasz M and Smyth JF: Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Biochem Pharmacol 56: 405-414, 1998.
7. Spanswick VJ, Cummings J, Ritchie AA and Smyth JF: Pharmacological determinants of the antitumour activity of mitomycin C. Biochem Pharmacol 56: 1497-1503, 1998.
8. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S and Workman P: Establishment of an isogenic human colon tumour model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 58: 1146-1155, 2000.
9. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J and Ross D: Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48: 499-504, 1995.
10. Winski SL, Hargreaves RH, Butler J and Ross D: A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 4: 3083-3088, 1998.
11. Berardini MD, Souhami RL, Lee CS, Gibson NW, Butler J and Hartley JA: Two structurally related diaziridinylbenzoquinones preferentially cross-link DNA at different sites upon reduction with DT-diaphorase. Biochemistry 32: 3306-3312, 1993.
12. Xing C and Skibo EB: Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones. Biochemistry 39: 10770-10780, 2000.
13. Loadman PM, Phillips RM, Lim LE and Bibby MC: Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. Biochem Pharmacol 59: 831-837, 2000.
14. Layne E: Spectrophotometric and turbimetric methods for measuring proteins. Methods Enzymol 3: 450-451, 1957.
15. Fang WF and Strobel HW: Effects of cyclophosphamide and polycyclic aromatic hydrocarbons on cell growth and mixed-function oxidase activity in a human colon tumor cell line. Cancer Res 42: 3676-3681, 1982.
16. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Comittee on Cancer Research (UKCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77: 1-10, 1998.
17. Langdon SP, Hendriks HR, Braakhuis BJM, Pratesi G, Berger DP, Fodstad O, Fiebig HH and Boven E: Preclinical phase II studies in human tumour xenografts: a European multicenter follow-up study. Eur J Cancer 5: 415-422, 1994.
18. Cummings J, MacPherson JS, Meikle I and Smyth JF: Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem Pharmacol 52: 979-990, 1996.
19. Hammond DK and Strobel HW: Human colon tumor cell line LS174T drug metabolizing system. Mol Cell Biochem 93: 95-105, 1990.
20. Plumb JA, Gerritsen M and Workman P: DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 70: 1136-1143, 1994.
21. Collard J, Matthew AM, Double JA and Bibby MC: EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 71: 1199-1203, 1995.
22. Nishiyama M, Saeki S, Aogi K, Hirabayashi N and Toge T: Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells differences in in vitro and in vivo systems. Int J Cancer 53: 1013-1016, 1993.
23. Mikami K, Naito M, Ishiguro T, Yano H, Tomida A, Yamada T, Tanaka N, Shirakusa T and Tsuruo T: Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Jap J Cancer Res 89: 910-915, 1998.
24. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis B.JM, Fodstad O, Langdon S and Fiebig HH: Phase II preclinincal drug screening in human tumour xenografts: a first European multicenter collaborative study. Cancer Res 52: 5940-5947, 1992.
25. Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ and Ross D: Relationship between NAD(P)H:quinone oxidoreductase I (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 61: 1509-1516, 2001.
26. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW and Ross D: Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorase. Cancer Res 54: 3196-3201, 1994